Crossbow Therapeutics, Inc logo

Crossbow Therapeutics, Inc

Established antibody engineering to target the untapped universe of intracellular cancer targets, founded by MPM Capital

45 employees · est. 2021 · Cambridge, United States

VS
Vaccentis logo

Vaccentis

VACCENTIS FOCUSES ON DEVELOPING IMMUNO-ONCOLOGY VACCINES UTILISING ITS AUTOLOGOUS TUMOUR VACCINE TECHNOLOGY PLATFORM

5 employees · est. 2006 · Zurich, Switzerland

Vaccentis is the older company (2021 vs 2006); Crossbow Therapeutics, Inc is the larger of the two.

Side-by-Side Comparison

Crossbow Therapeutics, Inc Vaccentis
Founded
2021 2006 older
Headquarters
Cambridge, United States Zurich, Switzerland
Employees
45 larger 5
Industry
Biotechnology, Health Care, Life Sciences Health Care
Funding Stage
Series B Not tracked yet
Total Funding
$157.00M Not tracked yet
Funding Rounds
2 Not tracked yet
Services
Development of TCR-mimetic antibodies, Cancer antigen targeting, Clinical trials, Therapeutic discovery and development Not tracked yet
Target Customers
Oncologists, Cancer research institutions, Pharmaceutical companies, Patients with cancer Not tracked yet
Taxonomy
Antibody Engineering, Intracellular Cancer Targets, Immunotherapy, T-cell Receptor Mimetic Antibodies, T-Bolt Therapies, Next-Generation Immunotherapy, Selective Cancer Targeting, Cancer Protein Targeting, Cancer Treatment Innovation, Therapeutic Potential, Cancer Patient Care, Precision Medicine, MPM Capital Immunotherapy, Cancer Vaccines, Oncology, Tumor Vaccine Technology, Autoimmune Oncology, Renal Cell Carcinoma, Metastatic Cancer Treatment, Clinical Research, Patient-Specific Medicines, Evidence-Based Medicine, Medical Product Development, Natural Medicine, Biopharmaceuticals
Website
crossbowtx.com vaccentis.com
Crossbow Therapeutics, Inc logo

About Crossbow Therapeutics, Inc

Crossbow Therapeutics, Inc, founded in 2021, is a pioneering biotechnology company headquartered in the United States. Their mission is to revolutionize cancer treatment through the development of TCR-mimetic antibodies, leveraging their proprietary T-Bolt™ therapies to precisely target cancer cells...

Vaccentis logo

About Vaccentis

Vaccentis is a health care startup with a focus on developing immuno-oncology vaccines utilizing its autologous tumor vaccine technology platform. The company was founded in 2006 and is currently in the late stage development of an autologous tumor vaccine for Renal Cell Carcinoma. Their medical div...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Crossbow Therapeutics, Inc and Vaccentis — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Crossbow Therapeutics,... and Vaccentis — by email.

Frequently Asked Questions

Crossbow Therapeutics, Inc — Established antibody engineering to target the untapped universe of intracellular cancer targets, founded by MPM Capital. Vaccentis — VACCENTIS FOCUSES ON DEVELOPING IMMUNO-ONCOLOGY VACCINES UTILISING ITS AUTOLOGOUS TUMOUR VACCINE TECHNOLOGY PLATFORM. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Crossbow Therapeutics, Inc has raised $157.00M while Vaccentis has raised undisclosed funding.
Crossbow Therapeutics, Inc and Vaccentis operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Crossbow Therapeutics, Inc with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy